Combining immunotherapy and radiotherapy for the STAR treatment

Jordan A Torok^{1

2}, Joseph K Salama^{3

4

5}

Affiliations

¹ Department of Radiation Oncology, Duke University Medical School, Durham, NC, USA.
² Duke Cancer Institute, Durham, NC, USA.
³ Department of Radiation Oncology, Duke University Medical School, Durham, NC, USA. joseph.salama@duke.edu.
⁴ Duke Cancer Institute, Durham, NC, USA. joseph.salama@duke.edu.
⁵ Radiation Oncology Service, Durham Veterans Affairs Medical Center, Durham, NC, USA. joseph.salama@duke.edu.

Comment

Jordan A Torok et al. Nat Rev Clin Oncol. 2019 Nov.

. 2019 Nov;16(11):666-667.

doi: 10.1038/s41571-019-0277-2.

Jordan A Torok^{1

2}, Joseph K Salama^{3

4

5}

¹ Department of Radiation Oncology, Duke University Medical School, Durham, NC, USA.
² Duke Cancer Institute, Durham, NC, USA.
³ Department of Radiation Oncology, Duke University Medical School, Durham, NC, USA. joseph.salama@duke.edu.
⁴ Duke Cancer Institute, Durham, NC, USA. joseph.salama@duke.edu.
⁵ Radiation Oncology Service, Durham Veterans Affairs Medical Center, Durham, NC, USA. joseph.salama@duke.edu.

No abstract available

Comment on

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P. Theelen WSME, et al. JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478. JAMA Oncol. 2019. PMID: 31294749 Free PMC article.